Totus Medicines

Unlike common practice, Totus populates its team with industry experts from a variety of disciplines, which has lead to an unprecedented volume of discovery and now a searchable knowledge base of drugs. It is perhaps also the reason why its platform allows screening at a rate more than 100,000 times faster than competitive technologies and hence in the 18 months of its fruition, Totus has developed the TOS-358 drug that targets the mutation that drives many cases of cancers.

The potential impact of its work is unimaginable, with Series A funding seeing its TOS-358 therapy already being introduced into the clinic. As it grows, it promises to do what it’s done for oncology for heart disease and neurodegeneration, a goal likely facilitated by a partnership with Mila, the Quebec artificial intelligence institute, whereby chemical biology knowledge is combined with AI expertise.